EU regulatory system tightens up further to silence the critics
This article was originally published in Clinica
Executive Summary
The run-up to the expansion of the EU from 15 to 25 countries has seen some of the most far-reaching shifts in the regulation of medical devices since the Directives were drafted over a decade ago. Mounting pressure over the last few years for tighter control over devices perceived to be particularly risky resulted in a series of landmark decisions in 2003 as the Commission showed itself no longer hesitant to use the regulatory tools available. Amanda Maxwell reports on a dynamic and challenging year
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.